Start Your Journey To Wealth

It takes just a few minutes to register.

Your Money - Best Investment ISA - Large Portfolio 2024
Boring money - Best for Customer Service 2022
Broker Chooser - Best broker for funds 2022

BIOPHARMA CREDIT PLC ORD USD0.01

Symbol: BPCR

This security went ex-dividend on 03/04/2025. Pay date is 07/05/2025

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Past Performance

  • 28th Apr 2020 to 28th Apr 20219.68%
  • 28th Apr 2021 to 28th Apr 20229.60%
  • 28th Apr 2022 to 28th Apr 20235.39%
  • 28th Apr 2023 to 28th Apr 20244.77%
  • 28th Apr 2024 to 28th Apr 20253.71%
Login Open an account

Key Information

Benchmark N/A
Sector IT Debt - Direct Lending
Gearing 100%
Ex-Dividend Date 3 Apr 2025
Dividend Pay Date 7 May 2025
Total Dividends - Year to Date0.07
Dividend Yield (%)8.1967

Net Asset Value (Nav)

Latest actual NAV 00.98
Latest actual NAV date 28/02/2025
NAV frequency Monthly
Premium/Discount -11.68%

Charges

Total Ongoing Charges 
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing. 		3.84%
Performance Fee No
AMC 1.00%
Our Platform Charge
We charge a platform fee of 0.30% per annum on the value of all stocks & shares held across all accounts, minimum £50 and maximum £600 per annum, charged pro-rata monthly in arrears. A full list of our rates and charges can be found here . 		0.30%

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here 		0.30%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available 		N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs 		3.84%
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Company

Business Summary

BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.

Financial Summary

BRIEF: For the six months ended 30 June 2024, Biopharma Credit PLC revenues increased 1% to $79.1M. Net income increased 1% to $71.8M. Revenues reflect Investment income increase of 9% to $83M. Net income also reflects Public relations fees decrease of 15% to $90K (expense), Selling/General/Admin Expe decrease of 24% to $50K (expense). Dividend per share remained flat at $0.04.

Performance

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Cumulative Performance

      1 month3 months6 months1 year3 years5 years
      -0.82% 2.20% 1.49% 3.71% 14.52% 37.67%

      Important Information
      Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.

      The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.

      Composition

      View Fund Allocation by:

      TOP 10 HOLDINGS TOP 10 ASSETS TOP 10 SECTORS TOP 10 GEOGRAPHIES

      Important Documents


      The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.

      Fund Provider Factsheet
      The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured. &nbsp;
      FUND PROVIDER FACTSHEET
      142,389 bytes PDF Document; last updated 28 Feb 2025
      Key Information Document This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
      KEY INFORMATION DOCUMENT
      188,677 bytes PDF Document; last updated 25 Mar 2025
      Annual Report A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
      ANNUAL REPORT
      2,822,872 bytes PDF Document; last updated 31 Dec 2024
      Semi Annual Report Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
      SEMI-ANNUAL REPORT
      1,214,124 bytes PDF Document; last updated 30 Jun 2024
      GET ADOBE READER

      Management Team

      Martin Friedman Pablo Legorreta Pedro Gonzalez de Cosio

      Martin Friedman has managed this fund for 8 years and 1 month.

      Martin Friedman There is currently no biography information for Martin Friedman.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Other investment trusts managed by Martin

      Name of Security Sole/Co Managed Since
      BP Crd Plc £ Co Mar 2017

      Pablo Legorreta has managed this fund for 8 years and 1 month.

      Pablo Legorreta There is currently no biography information for Pablo Legorreta.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Other investment trusts managed by Pablo

      Name of Security Sole/Co Managed Since
      BP Crd Plc £ Co Mar 2017

      Pedro Gonzalez de Cosio has managed this fund for 8 years and 1 month.

      Pedro Gonzalez de Cosio There is currently no biography information for Pedro Gonzalez de Cosio.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Other investment trusts managed by Pedro Gonzalez

      Name of Security Sole/Co Managed Since
      BP Crd Plc £ Co Mar 2017

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Revenue 150.03 135.73 218.14 103.86 110.01 150.89
      Gross profit 124.46 110.49 184.25 87.97 91.35 123.30
      Operating Profit/Loss 122.18 108.45 182.31 84.96 89.14 122.33
      Profit Before Tax 122.18 108.45 182.31 84.96 89.14 122.33
      Profit After Tax 122.18 108.45 182.31 84.96 89.14 122.33
      Equity Holders of Parent Company 122.18 108.45 182.31 84.96 89.14 122.33
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Non-Current Assets 1,162.20 1,201.36 1,223.65 1,265.90 1,194.83 1,116.13
      Total Current Assets 37.42 155.37 140.37 104.72 193.48 312.84
      Total Assets 1,199.62 1,356.73 1,364.02 1,370.62 1,388.31 1,428.97
      Total Liabilities 17.94 15.87 26.56 6.90 9.39 25.24
      Total Net Assets 1,181.68 1,340.86 1,337.45 1,363.72 1,378.92 1,403.74
      Shareholders Funds 1,181.68 1,340.86 1,337.45 1,363.72 1,378.92 1,403.74
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity 1,181.68 1,340.86 1,337.45 1,363.72 1,378.92 1,403.74

      Investment involves risk. You may get back less than invested.